---
title: Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response
  in HER2-positive breast cancer
date: '2024-02-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38319231/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240206170607&v=2.18.0
source: heidelberg[Affiliation]
description: Trastuzumab emtansine (T-DM1) was the first and one of the most successful
  antibody-drug conjugates (ADCs) approved for treating refractory HER2-positive breast
  cancer. Despite its initial clinical efficacy, resistance is unfortunately common,
  necessitating approaches to improve response. Here, we found that in sensitive cells
  T-DM1 induced spindle assembly checkpoint (SAC)-dependent immunogenic cell death
  (ICD), an immune-priming form of cell death. The payload of T-DM1 mediated ICD by
  ...
disable_comments: true
---
Trastuzumab emtansine (T-DM1) was the first and one of the most successful antibody-drug conjugates (ADCs) approved for treating refractory HER2-positive breast cancer. Despite its initial clinical efficacy, resistance is unfortunately common, necessitating approaches to improve response. Here, we found that in sensitive cells T-DM1 induced spindle assembly checkpoint (SAC)-dependent immunogenic cell death (ICD), an immune-priming form of cell death. The payload of T-DM1 mediated ICD by ...